What Can Brands Say About Health Without Crossing the Line?

In this episode, the National Advertising Division (NAD) examines the rapid rise in pharma and health-related cases—now a significant and growing share of its docket. The conversation explores some of today’s most closely scrutinized issues, including GLP-1 and compounded drug claims, and a wide variety of health claims from eczema to plantar fasciitis, as well as strikethrough pricing and endorsement disclosures.

This episode offers a timely look at how self-regulation is shaping industry practices through its wide-ranging guidance amidst increasing legal and regulatory pressure.

Related Resources:

• NAD Case #7455: Galderma Laboratories, L.P.
• NAD Case #7489: Agendia, Inc.
• NAD Case #7534: Midi Health, Inc.
• NAD Case #7518: Fletcher Family Medical
• NAD Case #7430: The Good Feet Store

Enjoyed this episode? Get caught up on past seasons of the Ad Watchers and subscribe to never miss an episode.

The post What Can Brands Say About Health Without Crossing the Line? appeared first on BBB National Programs.